??-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

francis888
2021-02-25

??

The first in the world! Moderna begins development of South African variant virus vaccine

Moderna宣布，该公司已经完成了相关候选疫苗的临床试验材料生产，已经向美国国立卫生研究院运送了候选疫苗，用于第一阶段的临床试验。

The first in the world! Moderna begins development of South African variant virus vaccine

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":361887850,"tweetId":"361887850","gmtCreate":1614220910170,"gmtModify":1704889749291,"author":{"id":3555286705263146,"idStr":"3555286705263146","authorId":3555286705263146,"authorIdStr":"3555286705263146","name":"francis888","avatar":"https://static.tigerbbs.com/1b0c4a363e7dcf591e676aeec9a54d06","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>??</p></body></html>","htmlText":"<html><head></head><body><p>??</p></body></html>","text":"??","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/361887850","repostId":2114974573,"repostType":4,"repost":{"id":"2114974573","kind":"news","pubTimestamp":1614218660,"share":"https://ttm.financial/m/news/2114974573?lang=en_US&edition=fundamental","pubTime":"2021-02-25 10:04","market":"hk","language":"zh","title":"The first in the world! Moderna begins development of South African variant virus vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2114974573","media":"华尔街见闻","summary":"Moderna宣布，该公司已经完成了相关候选疫苗的临床试验材料生产，已经向美国国立卫生研究院运送了候选疫苗，用于第一阶段的临床试验。","content":"<p>Moderna became the first vaccine manufacturer in the world to produce a vaccine against the South African variant strain.</p><p>On Wednesday, February 24, Moderna announced that it has completed the production of clinical trial materials for the relevant vaccine candidate, which targets the Novel Coronavirus variant strain (B.1. 351) first discovered in South Africa. Meanwhile, Moderna has shipped its vaccine candidate to the National Institutes of Health (NIH) for phase one clinical trials.</p><p>The NIAID agency under NIH will start this study after obtaining the safety clearance from the US FDA. When the trial is launched, NIAID will provide additional information on the clinicaltrials.gov website.</p><p>The statement pointed out that although preliminary data show that COVID-19 vaccine (mRNA-1273) developed by Moderna has a neutralizing response to the mutant strain, the company is adopting different strategies to deal with the mutant strain out of caution.</p><p>Moderna said it will evaluate whether the vaccine booster dose can improve the vaccine's immune response to the mutant strain, including a booster shot against the South African mutant strain (mRNA-1273. 351), a multivalent booster shot against the original strain and the mutant strain (mRNA-1273. 211), etc.</p><p>Moderna CEO Stéphane Bancel said that as human society seeks to defeat COVID-19 pandemic, it is necessary to remain vigilant and actively respond to new virus variants. At the same time, he mentioned that he was very worried about the emergence of \"mutant evolution\" outside the existing variants, especially in the current situation, it may not be clear which strain is already spreading.</p><p>Now vaccination is in a race with virus mutation. Earlier, the US FDA had begun to urge vaccine manufacturers to start research on new variants.</p><p>Earlier, scientists warned that we are at a critical moment: some people have been vaccinated, and at the same time, many viruses are spreading. The combination of these two factors may lead to the emergence of more contagious or deadly mutant strains.</p><p>The harm of the new variant is obvious-potentially reducing the effectiveness of vaccines, as well as reducing the effectiveness of treatments and causing reinfections in recovered populations.</p>","source":"wallstreetcn_api","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The first in the world! Moderna begins development of South African variant virus vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe first in the world! Moderna begins development of South African variant virus vaccine\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">华尔街见闻</strong><span class=\"h-time small\">2021-02-25 10:04</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna became the first vaccine manufacturer in the world to produce a vaccine against the South African variant strain.</p><p>On Wednesday, February 24, Moderna announced that it has completed the production of clinical trial materials for the relevant vaccine candidate, which targets the Novel Coronavirus variant strain (B.1. 351) first discovered in South Africa. Meanwhile, Moderna has shipped its vaccine candidate to the National Institutes of Health (NIH) for phase one clinical trials.</p><p>The NIAID agency under NIH will start this study after obtaining the safety clearance from the US FDA. When the trial is launched, NIAID will provide additional information on the clinicaltrials.gov website.</p><p>The statement pointed out that although preliminary data show that COVID-19 vaccine (mRNA-1273) developed by Moderna has a neutralizing response to the mutant strain, the company is adopting different strategies to deal with the mutant strain out of caution.</p><p>Moderna said it will evaluate whether the vaccine booster dose can improve the vaccine's immune response to the mutant strain, including a booster shot against the South African mutant strain (mRNA-1273. 351), a multivalent booster shot against the original strain and the mutant strain (mRNA-1273. 211), etc.</p><p>Moderna CEO Stéphane Bancel said that as human society seeks to defeat COVID-19 pandemic, it is necessary to remain vigilant and actively respond to new virus variants. At the same time, he mentioned that he was very worried about the emergence of \"mutant evolution\" outside the existing variants, especially in the current situation, it may not be clear which strain is already spreading.</p><p>Now vaccination is in a race with virus mutation. Earlier, the US FDA had begun to urge vaccine manufacturers to start research on new variants.</p><p>Earlier, scientists warned that we are at a critical moment: some people have been vaccinated, and at the same time, many viruses are spreading. The combination of these two factors may lead to the emergence of more contagious or deadly mutant strains.</p><p>The harm of the new variant is obvious-potentially reducing the effectiveness of vaccines, as well as reducing the effectiveness of treatments and causing reinfections in recovered populations.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://wallstreetcn.com/articles/3621285\">华尔街见闻</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://wallstreetcn.com/articles/3621285","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114974573","content_text":"Moderna成为全球第一家针对南非变异毒株生产疫苗的疫苗生产商。2月24日周三，Moderna宣布，该公司已经完成了相关候选疫苗的临床试验材料生产，该候选疫苗针对的是在南非首次发现的新冠病毒变异毒株（B.1.351）。与此同时，Moderna已经向美国国立卫生研究院（NIH）运送了候选疫苗，用于第一阶段的临床试验。NIH下属的NIAID机构将在获得美国FDA安全许可后启动这项研究。当试验启动后，NIAID将在clinicaltrials.gov网站上提供更多信息。声明指出，尽管初步数据显示，Moderna研发的新冠疫苗（mRNA-1273）对变异毒株产生了中和反应，但是出于谨慎考虑，该公司正采取不同的策略应对变异毒株。Moderna表示，将评估疫苗加强剂量是否能提高疫苗对变异毒株的免疫反应，包括针对南非变异毒株的加强针（mRNA-1273.351）、一种针对原始毒株和变异毒株的多价加强针（mRNA-1273.211）等。Moderna首席执行官Stéphane Bancel表示，在人类社会寻求战胜新冠疫情的时候，必须保持警惕，并积极应对新的病毒变种。他同时提到，非常担心现有变种之外出现“突变体进化“，特别是在当前情况下可能不清楚是哪种毒株已经在传播。如今疫苗接种正和病毒变异展开赛跑。早前美国FDA已经开始敦促疫苗生产商开始针对新的变种进行研究。此前有科学家警告，当前处于一个关键时刻：一部分人接种了疫苗，与此同时有很多病毒在传播，这两个因素的结合将可能导致出现更具传染性或更致命的变异毒株。新变种的危害是显而易见的——可能降低疫苗的有效性，也可能降低治疗的有效性并导致康复人群再次感染。","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2053,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}